ES2193937T3 - Nueva forma cristalina de la sal de potasio de (s) -omeprazol. - Google Patents

Nueva forma cristalina de la sal de potasio de (s) -omeprazol.

Info

Publication number
ES2193937T3
ES2193937T3 ES00903058T ES00903058T ES2193937T3 ES 2193937 T3 ES2193937 T3 ES 2193937T3 ES 00903058 T ES00903058 T ES 00903058T ES 00903058 T ES00903058 T ES 00903058T ES 2193937 T3 ES2193937 T3 ES 2193937T3
Authority
ES
Spain
Prior art keywords
potassium salt
omeprazol
crystal form
new crystal
omeprazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00903058T
Other languages
English (en)
Inventor
Maths Nilsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2193937T3 publication Critical patent/ES2193937T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La sal de potasio de (S)-omeprazol en forma B, caracterizada por ser una forma hidratada, por ser cristalina y por proporcionar un patrón de difracción de rayos X de polvo que exhibe sustancialmente los siguientes valores d: **(Esquema)**
ES00903058T 1999-01-28 2000-01-18 Nueva forma cristalina de la sal de potasio de (s) -omeprazol. Expired - Lifetime ES2193937T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9900274A SE9900274D0 (sv) 1999-01-28 1999-01-28 New compound

Publications (1)

Publication Number Publication Date
ES2193937T3 true ES2193937T3 (es) 2003-11-16

Family

ID=20414267

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00903058T Expired - Lifetime ES2193937T3 (es) 1999-01-28 2000-01-18 Nueva forma cristalina de la sal de potasio de (s) -omeprazol.

Country Status (40)

Country Link
US (1) US6511996B1 (es)
EP (1) EP1149090B1 (es)
JP (1) JP2002535401A (es)
KR (1) KR100624054B1 (es)
CN (1) CN1231477C (es)
AR (1) AR022425A1 (es)
AT (1) ATE236899T1 (es)
AU (1) AU768676B2 (es)
BG (1) BG65060B1 (es)
BR (1) BR0007647A (es)
CA (1) CA2357744C (es)
CZ (1) CZ300504B6 (es)
DE (1) DE60002042T2 (es)
DK (1) DK1149090T3 (es)
DZ (1) DZ3001A1 (es)
EE (1) EE04240B1 (es)
EG (1) EG23980A (es)
ES (1) ES2193937T3 (es)
HK (1) HK1041259B (es)
HU (1) HU226766B1 (es)
ID (1) ID30095A (es)
IL (1) IL144107A0 (es)
IS (1) IS2019B (es)
MY (1) MY119095A (es)
NO (1) NO319719B1 (es)
NZ (1) NZ512804A (es)
PL (1) PL197881B1 (es)
PT (1) PT1149090E (es)
RS (1) RS50200B (es)
RU (1) RU2237666C2 (es)
SA (1) SA00200895B1 (es)
SE (1) SE9900274D0 (es)
SI (1) SI1149090T1 (es)
SK (1) SK285626B6 (es)
TN (1) TNSN00017A1 (es)
TR (1) TR200102138T2 (es)
TW (1) TWI269795B (es)
UA (1) UA71594C2 (es)
WO (1) WO2000044744A1 (es)
ZA (1) ZA200105526B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20070060556A1 (en) * 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2007532677A (ja) * 2004-04-16 2007-11-15 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤、および運動促進薬の組み合わせ
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN103772360A (zh) * 2004-06-24 2014-05-07 阿斯利康(瑞典)有限公司 制备用于制备艾美拉唑钠盐的结晶修饰物的新方法
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
CN100384839C (zh) * 2006-02-17 2008-04-30 中国科学院上海有机化学研究所 [(取代的吡啶基)甲基]亚磺酰基-1h-苯并咪唑类化合物及其对映体的锌盐的制备方法
EP2040710A2 (en) * 2006-06-21 2009-04-01 Glenmark Pharmaceuticals Limited Novel polymorph of esomeprazole potassium and process for its preparation
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
US7906678B2 (en) 2006-12-04 2011-03-15 Bayer Schering Pharma Aktiengesellschaft Crystalline potassium salt of lipoxin A4 analogs
FR2920428B1 (fr) * 2007-08-29 2012-06-15 Univ Rouen Procede de dedoublement de sels de l'omeprazole
WO2009074997A2 (en) * 2007-12-10 2009-06-18 Lee Pharma Ltd. A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
SG181535A1 (en) 2009-12-08 2012-07-30 Codexis Inc Synthesis of prazole compounds
CN102319223B (zh) * 2011-09-21 2013-06-19 石药集团欧意药业有限公司 一种埃索美拉唑冻干制剂及其制备方法
CN102633776B (zh) * 2012-03-28 2014-06-18 中山市仁合药业有限公司 一种埃索美拉唑及其钠盐的制备方法
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
CN1138534C (zh) 1994-07-08 2004-02-18 阿斯特拉曾尼卡有限公司 多单元片剂
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
GB9423970D0 (en) 1994-11-28 1995-01-11 Astra Ab Oxidation
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B

Also Published As

Publication number Publication date
AU768676B2 (en) 2003-12-18
RU2237666C2 (ru) 2004-10-10
TNSN00017A1 (fr) 2005-11-10
SK285626B6 (sk) 2007-05-03
DK1149090T3 (da) 2003-06-30
EE04240B1 (et) 2004-02-16
NZ512804A (en) 2003-07-25
EG23980A (en) 2008-02-27
DE60002042T2 (de) 2003-12-18
IL144107A0 (en) 2002-05-23
CA2357744C (en) 2009-06-16
DZ3001A1 (fr) 2004-03-27
PL197881B1 (pl) 2008-05-30
HUP0105313A2 (hu) 2002-05-29
KR100624054B1 (ko) 2006-09-18
EP1149090B1 (en) 2003-04-09
HUP0105313A3 (en) 2003-01-28
EE200100395A (et) 2002-10-15
BG105841A (en) 2002-04-30
NO20013665D0 (no) 2001-07-26
NO319719B1 (no) 2005-09-05
HK1041259B (zh) 2003-10-24
ATE236899T1 (de) 2003-04-15
TR200102138T2 (tr) 2001-12-21
UA71594C2 (uk) 2004-12-15
HU226766B1 (en) 2009-09-28
SE9900274D0 (sv) 1999-01-28
AU2469400A (en) 2000-08-18
CN1231477C (zh) 2005-12-14
RS50200B (sr) 2009-07-15
ZA200105526B (en) 2002-10-04
TWI269795B (en) 2007-01-01
JP2002535401A (ja) 2002-10-22
IS5989A (is) 2001-07-05
SA00200895B1 (ar) 2006-11-11
MY119095A (en) 2005-03-31
NO20013665L (no) 2001-07-26
CZ300504B6 (cs) 2009-06-03
KR20010101699A (ko) 2001-11-14
EP1149090A1 (en) 2001-10-31
SK10372001A3 (sk) 2002-02-05
CA2357744A1 (en) 2000-08-03
BR0007647A (pt) 2001-10-16
SI1149090T1 (en) 2003-10-31
DE60002042D1 (de) 2003-05-15
IS2019B (is) 2005-06-15
HK1041259A1 (en) 2002-07-05
CZ20012730A3 (cs) 2002-02-13
AR022425A1 (es) 2002-09-04
PT1149090E (pt) 2003-07-31
WO2000044744A1 (en) 2000-08-03
BG65060B1 (bg) 2007-01-31
ID30095A (id) 2001-11-01
CN1339034A (zh) 2002-03-06
YU53801A (sh) 2004-07-15
US6511996B1 (en) 2003-01-28

Similar Documents

Publication Publication Date Title
ES2193937T3 (es) Nueva forma cristalina de la sal de potasio de (s) -omeprazol.
GB2270075B (en) Substituted 2-phenyl-3-methoxypropenoate fungicides
MY152846A (en) New salts of valsartan
GEP20084399B (en) Crystal forms of azithromycin
ES2139559T3 (es) Nueva forma cristalina de omeprazol.
ES2173054T3 (es) Base cristalina de citalopram.
PT1296947E (pt) Forma cristalina alfa do sal de terc.-butilamina do perindopril
RS50071B (sr) Novi oblik soli pantoprazola
FR2676914B1 (fr) Prothese femorale anatomique.
DE69016785D1 (de) Auswechselbare Höchstintegrationspackung.
BR0312996A (pt) Sal de (s)-pantoprazol e seus hidratos
TR199501392A2 (tr) Yeni kristalli sefem-asit katma tuzlari ve bunlarin üretilmesine mahsus usul.
ES2183650T3 (es) Cristal de diuridina tetrafosfato o sal correspondiente y procedimiento de fabricacion.
TW351718B (en) Acylated aminoalkanimidazoles and -triazoles
IT1318457B1 (it) Cartuccia per la perforazione dell'orecchio.
HU9202667D0 (en) Method for producing and applying a new derivative of beta-phenyl-isoserine
CH685526GA3 (fr) Boîte de montre.
ID27027A (id) 2-aminopiridin yang mengandung substituen cincin lebur
BR9307232A (pt) 4-Estrenos ligados por meio de ponte-19,11 com efic cia gestag-nica
FI980901A (fi) Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
ATE323493T1 (de) Gesteuerte freisetzung von antidepressiva
IT1314486B1 (it) Torcia per attivita' subacquea.
AP9901637A0 (en) Crystalline hydrated sodium salt of (E)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidin-3-ylidene methyl)-1H-indole-2-carboxylic acid.
BR9910804A (pt) Processo para a preparação de sais cristalinos de amoxilina
MA26840A1 (fr) Cristaux d'inhibiteur d'echangeur sodium-hydrogene de type 1